| Name | Title | Contact Details |
|---|
Castle Biosciences, Inc. specializes in diagnostic tests for cancers. Founded in 2008, the company goal has been to help advance the care for cancers through objective testing. Our team works with outstanding members of the oncology community throughout the discovery, development and utilization of these tests. Currently, Castle Biosciences has tests to help doctors treat glioblastoma, uveal melanoma, low grade gliomas. We anticipate tests for thymoma and esophageal cancer to be on the market in the near future (1Q-1H, 2012) as they are going through final validation.
Headquartered in Tucson, Arizona, HTG is focused on advancing precision medicine. The company`s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount.
FluroTech is a technology and marketing company whose core business is focused on the commercialization of new technologies in the cannabis industry. FluroTech`s proprietary spectroscopy-based technology allows for the testing and identification of organic and inorganic compounds contained within biological samples derived from cannabis plants. Using the technology that was developed at the University of Calgary in conjunction with the University of Alberta, FluroTech has developed a two-part solution comprising an instrument called the CompleTest™ and consumable testing kits.
Arbor Vita Corporation is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Principia Biopharma is a privately-held biopharmaceutical company focused on the discovery and development of best-in-class small molecule drugs for autoimmune diseases and cancer. The company uses its proprietary technology, licensed from the University of California San Francisco, to enable a new approach to making small molecules that are potent, safe and have antibody-like specificity. Principia raised $40 million in a Series A round of financing from a leading group of healthcare investors, including New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SROne and Mission Bay Capital.